HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

By HospiMedica International staff writers
Posted on 20 Mar 2024
Print article
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections, including neutropenic sepsis—a potentially fatal reaction to infection and a severe complication of chemotherapy. Identifying the signs of neutropenic sepsis can be challenging, leading to a stressful and expensive treatment process. Consequently, all chemotherapy patients feeling ill are advised to seek emergency care to check for neutropenic sepsis. Unfortunately, half of these patients do not receive antibiotics quickly enough, while the other half, not at risk of neutropenic sepsis, unnecessarily visit the emergency department.

52North Health Ltd. (Cambridge UK) has developed NeutroCheck, a groundbreaking approach aimed at enhancing the safety and well-being of cancer patients. This innovation combines a finger-prick blood test with an AI-powered digital platform, allowing patients to evaluate their neutropenic sepsis risk at home. This affordable, user-friendly device measures the patient's neutrophil count and CRP level (a marker for sepsis) from just a small blood sample. By inputting this data into the app, along with other patient information, the AI technology provides an accurate risk assessment. Low-risk patients might stay home or receive community care, while high-risk patients get prioritized for urgent emergency department treatment and antibiotics.

NeutroCheck is the first economical, portable tool that measures both cells and solutes in a single sample using adapted lateral flow technology—a method previously limited to measuring solutes. It simultaneously assesses neutrophils and CRP levels, with buffers incorporated within the device released automatically with a simple dial turn. Developed in collaboration with over 100 patients, caregivers, and healthcare professionals, NeutroCheck aims to streamline the triage process for neutropenic sepsis patients, reducing unnecessary emergency visits, lowering healthcare costs, and potentially saving lives by ensuring timely antibiotic administration.

Gold Member
12-Channel ECG
CM1200B
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Mattress Replacement System
Apollo Infant Dynamic
New
Prostate Cancer MRI Analysis Tool
DynaCAD Urology

Print article

Channels

Critical Care

view channel
Image: The Atmo Gas Capsule measures gases as it travels through the GI tract and transmits the data wirelessly (Photo courtesy of Atmo Biosciences)

Ingestible Smart Capsule for Chemical Sensing in the Gut Moves Closer to Market

Intestinal gases are associated with several health conditions, including colon cancer, irritable bowel syndrome, and inflammatory bowel disease, and they have the potential to serve as crucial biomarkers... Read more

Surgical Techniques

view channel
Image: The Elana Heart Bypass System is designed to make suturing obsolete (Photo courtesy of AMT Medical)

Pioneering Sutureless Coronary Bypass Technology to Eliminate Open-Chest Procedures

In patients with coronary artery disease, certain blood vessels may be narrowed or blocked, requiring a stent or a bypass (also known as diversion) to restore blood flow to the heart. Bypass surgeries... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more